Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | TNKS | O95271 | 2/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 6/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866633 | 0.90 | TNKS (0.50) | BACE1TNKSTNKS2PGRIKBKB | |
| SCHEMBL31472193 | 0.90 | TNKS (0.50) | BACE1TNKSTNKS2PGRIKBKB | |
| SCHEMBL15004855 | 0.86 | TNKS (0.51) | BACE1TNKSTNKS2OPRM1PGR | |
| SCHEMBL24481758 | 0.86 | TNKS (0.51) | BACE1TNKSTNKS2PGR | |
| SCHEMBL31472145 | 0.86 | TNKS (0.51) | BACE1TNKSTNKS2OPRM1PGR | |
| SCHEMBL4719403 | 0.85 | TNKS (0.50) | BACE1TNKSTNKS2OPRM1PGR | |
| SCHEMBL15650376 | 0.82 | TNKS (0.46) | BACE1TNKSTNKS2PGRHTR2A | |
| SCHEMBL19235278 | 0.81 | BACE1 (0.53) | BACE1TNKSTNKS2OPRM1HTR2C | |
| SCHEMBL20955106 | 0.80 | BACE1 (0.51) | BACE1TNKSTNKS2OPRM1PGR | |
| SCHEMBL3257846 | 0.80 | BACE1 (0.51) | BACE1TNKSTNKS2OPRM1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | BACE1 3420/4885TNKS 3604/4885TNKS2 3815/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | BACE1 3511/4885TNKS 3690/4885TNKS2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.